Clinical Trials Logo

Filter by:
NCT ID: NCT04935801 Completed - Dengue Clinical Trials

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus

Start date: August 2, 2021
Phase: Phase 1
Study type: Interventional

This trial aims to test the safety of 2 doses of a T-cell priming specific cocktail of Dengue viruses peptides representing all 4 DENV serotypes and mounted on a gold nanoparticle. NOTE: This is the master protocol of a prospective 2-stage adaptive trial, which aims to add and test a Coronavirus vaccine candidate as well, in an identical trial design.

NCT ID: NCT04933305 Completed - Obesity Clinical Trials

Microstructure of Ingestive Behavior and Body Weight Loss After Roux-en-Y Gastric Bypass

Drinkometer
Start date: April 1, 2019
Phase:
Study type: Observational

Studies of appetitive behavior in humans after RYGB have produced ambiguous results. It therefore remains unclear whether there are fundamental shifts in the palatability of high-fat and sugary foods after RYGB or simply a decrease in the appetitive drive to ingest them. Moreover, learning processes may play a role as changes in diet selection progress with time in rats after RYGB. However, direct measures of an altered food selection in humans after RYGB are rare and both the durability of the phenomenon as well as the role of experience for changes in food selection remain elusive.

NCT ID: NCT04932135 Completed - Graves Disease Clinical Trials

Resting Heart Rate Monitoring for Optimized Treatment and Surveillance of Hyperthyroidism

PULSAR
Start date: June 8, 2021
Phase:
Study type: Observational

The investigators want to investigate if a continuous heart rate monitoring with a wrist worn fitnesstracker can be useful in the treatment and surveillance of patients suffering from Graves' disease.The aim of our research project is two-fold: First, to evaluate the use of continuous heart rate monitoring as a potential substitute for hormone measurements during treatment of hyperthyroidism. Second, to use continuous heart rate monitoring as a tool for early detection of relapse after discontinuation of antithyroid drugs.

NCT ID: NCT04928937 Completed - Obesity Clinical Trials

Pharmacokinetics of SSRI/SNRI After Bariatric Surgery

Start date: February 1, 2017
Phase:
Study type: Observational [Patient Registry]

Psychiatric disorders and treatment with antidepressants SSRI/SNRI (selective serotonin reuptake inhibitors/ serotonin-norepinephrine reuptake inhibitors) are common in people with morbid obesity who are candidates for bariatric surgery. Although longitudinal assessments reveal positive effects of bariatric surgery on quality of life and mood, depressive disorders may also deteriorate after bariatric surgery. There is few and inconsistent data about the postoperative pharmacokinetics of SSRI/SNRI. The aims of our study were to provide comprehensive data about the postoperative bioavailability of SSRI/SNRI, and the clinical effects on the course of depression.

NCT ID: NCT04925830 Completed - Inhibition Clinical Trials

Exploring the Impact of Biofeedback on the Inhibitory Control of Healthy Older Adults

I-BF
Start date: August 18, 2020
Phase: N/A
Study type: Interventional

Inhibitory control refers to the conscious and voluntary suppression of predominant responses when they are automatic, inappropriate, or incorrect. Inhibitory control plays a key role in self-regulation and self-control behaviors in many different areas of everyday life. During aging, their decline would impact executive functioning and mental health. Recently, physiological training methods including heart rate variability biofeedback (HRV-BF), based on heart rate and respiration measurements, and hemoencephalography biofeedback (nirHEG NF), based on the hemodynamic response of some prefrontal regions, have proven to have a positive impact on executive functions. In this study, subjects of the experimental group were exposed to biofeedback training during 10 sessions, once a week, and their results compared to those of the control group, which did not receive biofeedback training. This study aims to explore the impact of training that combines two innovative techniques, such as heart rate variability biofeedback and hemoencephalography biofeedback on the inhibitory control of older adults. We expect positive effects of biofeedback training on the inhibition tasks and the targeted physiological parameters. Primary objective - We intend to demonstrate that heart rate variability biofeedback training coupled with hemoencephalography biofeedback training can be effective methods to counteract the decline of inhibitory control in older adults. Secondary objective - We intend to demonstrate that heart rate variability biofeedback and hemoencephalography biofeedback can effectively increase heart rate variability and blood flood oxygenation.

NCT ID: NCT04915599 Completed - Oral Mucositis Clinical Trials

Feasibility and Patient Reported Tolerance of Cryotherapy With the Cooral ® Mouth Cooling Device [MCD) in Patients Undergoing Radiation Therapy

CooRay
Start date: June 22, 2021
Phase: N/A
Study type: Interventional

This study is to investigate the use of the Cooral ® standardized CyT device to achieve a constant and reproducible cooling of the oral mucosa to prevent OM in patients undergoing RT in the head and neck region.

NCT ID: NCT04914702 Completed - Oncology Clinical Trials

Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.

Start date: September 16, 2021
Phase:
Study type: Observational

In this pilot study the feasibility continous recording of vital signs in pediatric patients under chemotherapy for cancer, is studied. Vital signs and are recorded with two different wearable devices (WDs): Everion®, by Biovotion (now Biofourmis), Zurich, Switzerland and CORE® by GreenTEG, Zurich, Switzerland. Patients can choose if they want to wear one or both WDs during this study. Those opting to wear two WDs can choose if they want to wear them in parallel, or sequentially. Results from the two different WDs will be compared. Study duration for each participant is 14 days per device.

NCT ID: NCT04912622 Completed - Retinal Disease Clinical Trials

RPE Characterisation With Transscleral Optical Phase Imaging in Retinal Disorders

CEL01LUKS
Start date: May 19, 2021
Phase: N/A
Study type: Interventional

Accumulating evidence suggest that the functional unit of photoreceptor/ retinal pigment epithelium (RPE)/Bruch's membrane/choriocapillaris plays a key role in pathophysiologic processes of a wide range of medical retinal disorders of the eye. Little is known about in vivo morphometric characteristics of human RPE cells as in vivo observation of these cells was so far technically challenging and hence nearly impossible to implement in a clinical setting. Transscleral optical phase imaging is a novel in-vivo microscopy technique allowing human RPE imaging on a cellular level with the potential of clinical application in a multimodal retinal imaging approach for diagnostic purpose in medical retina patients.

NCT ID: NCT04911985 Completed - Cardiogenic Shock Clinical Trials

Viability of Pulsioflex Monitoring in ICU

Start date: July 1, 2015
Phase:
Study type: Observational

Goal of the Study is to Study the precision of semi-invasive cardiac index monitoring by means of the ProAQT (PULSION Medical Systems SE) sensor, whereby the pulmonary artery catheter will serve as gold standard.

NCT ID: NCT04911660 Completed - Kidney Stone Clinical Trials

Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers

SWEETSTONE
Start date: August 25, 2021
Phase: Phase 2
Study type: Interventional

The aim of this study is to test the effect of a new drug on the composition of the urine in kidney stone patients. This new drug (Jardiance®, substance: empagliflozin) is currently approved in Switzerland for the treatment of patients with diabetes. Data from previous studies with and without diabetes suggest that it may have a beneficial effect on the composition of the urine and thereby reduce the risk of developing kidney stones.